The Positive Lymph Node Ratio Predicts Long-Term Survival in Patients with Operable Thoracic Esophageal Squamous Cell Carcinoma in China

2012 ◽  
Vol 20 (5) ◽  
pp. 1653-1659 ◽  
Author(s):  
Xue Hou ◽  
Jin-Chang Wei ◽  
Ying Xu ◽  
Rong-Zhen Luo ◽  
Jian-Hua Fu ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Lymph Node ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Lymph Node Ratio ◽  
Positive Lymph Node ◽  
Term Survival ◽  
Node Ratio

scholarly journals Is lymph node ratio in surgical treatment of esophageal squamous cell carcinoma better than classic TNM system?

2017 ◽  
Vol 28 ◽  
pp. iii33
Author(s):  
Vítor Devezas ◽  
Hugo Santos-Sousa ◽  
Beatriz Caldeira ◽  
Monica Torres ◽  
Márcio Mesquita ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Lymph Node ◽  
Surgical Treatment ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Lymph Node Ratio ◽  
Tnm System ◽  
Node Ratio ◽  
Better Than

scholarly journals SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Yushi Nagaki ◽  
Satoru Motoyama ◽  
Yusuke Sato ◽  
Akiyuki Wakita ◽  
Hiromu Fujita ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Prognostic Factors ◽  
Lymph Node ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Neoadjuvant Chemoradiotherapy ◽  
Reduction Rate ◽  
Term Survival

Abstract Background A pathological complete response (pCR) after neoadjuvant chemoradiotherapy (NACRT) ensures long-term survival in esophageal squamous cell carcinoma (ESCC) patients following esophagectomy, but pCR patients are a minority. The aim here was to identify prognostic factors in patients with non-pCR ESCC after NACRT. Methods This is a retrospective study. Investigated were 5-year overall survival (OS), disease-specific survival (DSS), and relapse-free survival (RFS) among non-pCR ESCC patients divided into pT0N0, primary site pCR (pT0N+), lymph node pCR (pT+N0), and non-pCR in both the tumor and lymph node (pT+N+) subgroups after NACRT and esophagectomy. Focusing on the SUVmax reduction rate in the primary tumor in 88 patients who underwent FDG-PET before and after NACRT, we used univariate and multivariate Cox proportional hazard models to identify prognostic factors. Results Although there were no significant survival differences among non-pCR ESCC patients with pT0N+, pT+N0, or pT+N+, survival rate among pT+N+patients was the poorest. After setting a 60% cutoff for the SUVmax reduction rate in the tumor, RFS curves for non-pCR patients significantly differed between patients above the cutoff and those below it. For pT+N+ patients, the SUVmax reduction rate (<60% vs ≥ 60%) was an independent prognostic factor of OS, DSS, and RFS. Conclusion Because ESCC patients with SUVmax reduction rates of <60% in the tumor after NACRT and categorized as pT+N+ after NACRT had significantly poorer prognoses, even after esophagectomy, a change in treatment strategy may be an option to improve survival.

Sign in / Sign up

Export Citation Format

Share Document